W3C home > Mailing lists > Public > public-semweb-lifesci@w3.org > April 2018

PDDI Min Info Model Task Force - Please review penultimate Community Group Note by 5/17/18

From: Richard Boyce <rdb20@pitt.edu>
Date: Thu, 26 Apr 2018 11:15:44 -0400
To: public-semweb-lifesci@w3.org, public-hclscg@w3.org, linikujp@gmail.com, brian.lebaron@va.gov, hocumrx@gmail.com, CJVITALE@PARTNERS.ORG, Cui.Tao@uth.tmc.edu, malone@Pharmacy.arizona.edu, daniela.oliveira@insight-centre.org, eric@squishymedia.com, draper.evan@mayo.edu, glilly@glilly.net, gmcevoy@ashp.org, jschneider@pobox.com, harryh@pitt.edu, jeffnielson@gmail.com, sundaram.medimmune@gmail.com, jschneider@pobox.com, jrhorn@u.washington.edu, jklimek@ncpdp.org, jp@rxdoc.me, jmbanda@stanford.edu, kim.nolen@pfizer.com, laura.slaughter@gmail.com, lori.idemoto@gmail.com, peters@pharmacy.arizona.edu, maria.herrero@kcl.ac.uk, mkbreit@mail.med.upenn.edu, MBrochhausen@uams.edu, matthias.samwald@meduniwien.ac.at, michel.dumontier@stanford.edu, Michael.Miller@systemsbiology.org, mike@easterninformatics.com, michael.liebman@ipqanalytics.com, mail@jackpo.org, nancy@worldvista.org, nick.tatonetti@columbia.edu, hassanzadeh@us.ibm.com, yongqunh@med.umich.edu, olivier@nlm.nih.gov, beyan@dbis.rwth-aachen.de, nytroe@idi.ntnu.no, rthirumaran@genelex.com, ratnesh.sahay@insight-centre.org, rdb20@pitt.edu, Freimuth.Robert@mayo.edu, Sam.habiel@gmail.com, scott.nelson.rx@gmail.com, serkanayvaz@gmail.com, SPE@USP.org, valerie@genelex.com, xjing2007@gmail.com, eag60@pitt.edu
Cc: "Wiggins, Austin" <auw9@pitt.edu>
Message-ID: <9438c258-401f-4492-48d8-18bb862d1a14@pitt.edu>
Dear Task Force Colleagues,

I am pleased to announce that we have completed major revision on the 
draft community group noteĀ  on the topic of a potential drug-drug 
interaction (PDDI) minimum information model. The content of the note is 
not very different from prior versions but the organization and format 
is considerably changed with the goal of making it a much more usable 
report for a technical audience.

I have checked with the other editors on this note and have received 
very positive feedback. I am asking all contributors for any final 
feedback before we officially publish as W3C Community Group Note.

You can view the note here:

- Temporary web location (what the note will ultimately look like): 
https://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/hcls-drug-drug-interaction/index.html 


- Word and PDF versions in case you want to make edits/comments (please 
note that the final version of this will be rendered as shown on the web 
version)

Please reply directly to me or on the Community Group mailing list 
(public-hclscg@w3.org) with any comments, edits, or concerns within 
three weeks (by May 17th). Please ensure that your name and affiliation 
is written correctly. Also, an funding acknowledgement that needs 
mentioned.

thanks a bunch!

-Rich

-- 
Richard D Boyce, PhD
Associate Professor of Biomedical Informatics and Clinical and Translational Science in the Clinical and Translational
Science Institute
Director of the Informatics Core for the Center of Excellence for Natural Product- Drug Interaction Research (NaPDI)
Faculty, Center for Pharmaceutical Policy and Prescribing
Faculty, Geriatric Pharmaceutical Outcomes and Gero-Informatics Research and Training Program
University of Pittsburgh
rdb20@pitt.edu
Office: 412-648-9219
Twitter: @bhaapgh



Received on Thursday, 26 April 2018 15:16:57 UTC

This archive was generated by hypermail 2.3.1 : Thursday, 26 April 2018 15:17:01 UTC